Profound Medical Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Profound Medical Corp. on January 13, 2026, with the earliest event reported on that date. The Company, incorporated in Ontario, Canada, is listed on The Nasdaq Stock Market under the symbol "PROF". The filing primarily addresses a significant clinical milestone regarding the Company's TULSA-PRO® system.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific event and does not contain financial statements or quantitative financial data.
Material Changes and Events
- Clinical Milestone: On January 15, 2026, the Company announced that Mount Sinai Hospital treated its first prostate cancer patient using the TULSA-PRO® system.
- Regulatory Disclosure: The announcement was made pursuant to Item 7.01 (Regulation FD Disclosure) to ensure fair disclosure of material non-public information.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of specific risks and contingencies beyond the standard legal disclaimers. The press release referenced in Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings.
Investor Verification Checklist
- Verify the clinical outcomes and patient data associated with the first treatment at Mount Sinai Hospital.
- Review the full text of the press release (Exhibit 99.1) for details on the TULSA-PRO® system's performance.
- Monitor future filings for any financial impact or commercialization updates resulting from this clinical milestone.
- Confirm the Company's ongoing regulatory status and any additional approvals required for broader deployment.